Delivering life-enhancing renal care responsibly: Diaverum releases its 2024 ESG report
Malmö, Sweden, 24 June 2025 – Diaverum, the Swedish-born global renal care provider, today announced the release of its 2024 Environmental, Social and Governance (ESG) Report. The report includes information related to the company’s non-financial performance last year and underscores how its mission to deliver life-enhancing renal care is intrinsically linked to its commitment to ESG excellence.
2024 marked a pivotal chapter as Diaverum integrated further with M42, its strategic investor, joining its newly created Global Patient Care platform earlier this year. This development is allowing the company to strengthen its ability to deliver high-quality, digitally connected care across borders – combining Diaverum’s clinical expertise with M42’s innovation in AI, data, and precision health.
ESG is woven into Diaverum’s corporate strategy and operations, ensuring a stakeholder-focused approach to how it conducts business. To support this, the company has developed its own ESG framework, structured around five strategic pillars that reflect its commitment to continuously improving non-financial performance. Each of such pillars is explored in detail throughout the 2024 report, along with its ambitions for 2025 and the policies already in place to support them.
2024 ESG pillar performance highlights:
- Patients: Diaverum continued to strengthen its patient-centric approach by expanding its proprietary Patient Experience Framework to over 316 clinics, covering 95% of operating countries. Through tools like the d.CARE smartphone app and expanded educational resources, the company enhanced health literacy and patient empowerment.
- Access to care: beyond dialysis, Diaverum deepened its commitment to preventive healthcare, with pre-dialysis programmes in 11 countries and structured diabetes management initiatives in Romania and Brazil. The organisation supported community-based CKD awareness efforts and promoted kidney health. Meanwhile, its holiday dialysis programme, d.HOLIDAY, delivered over 76,000 treatments in 2024 and launched d.HOLIDAY Fly Back – an initiative that ensures patients on transplant waiting lists can travel and return safely for surgery when needed, at no personal cost.
- Employees and well-being: Diaverum’s people-first culture was reflected in strong engagement scores. 82% of employees recommended Diaverum as a good place to work and 88% felt motivated to improve services to patients, well above its 2025 ambitions of 70% and 75% respectively.
- Operating responsibly: the company reinforced its governance standards through enhanced compliance training, expanded ESG oversight, and stronger integration into risk management, with a 100% training completion rate achieved in 2024. At the same time, cybersecurity and data protection remained central to securing patient information and digital platforms.
- Environment: in line with its net zero 2050 ambition, Diaverum enhanced its carbon footprint accounting across Scopes 1 and 2, improved its Scope 3 accounting, and launched a climate transition roadmap. Its solar energy programme, implemented in 23 clinics, produced 795 MWh of renewable energy, while efforts to reduce water usage and clinical waste continued across all 24 countries of operation. Additionally, the company launched a global climate risk assessment and a performance dashboard to monitor environmental impact.
Rafael Romanini, Diaverum Group Chief Executive Officer, stated: “As global demand for dialysis grows, we remain focused on providing life-enhancing renal care – wherever and whenever it is needed. ESG is increasingly shaping our strategy, decisions, and culture, ensuring we serve not only our patients, but also the communities and planet we all depend on.
“Our ESG journey is grounded in the belief that responsible, sustainable healthcare is not only possible – but essential. Together with M42, we are broadening access to kidney care, improving outcomes, and helping build more resilient, sustainable healthcare systems”.
Stephanie de Sury, Diaverum Global ESG Manager, added: “Throughout 2024, we focused on embedding sustainability more deeply into our core strategy and daily operations. This report is a testament to the collective efforts of our teams across 24 countries. It also reflects our ongoing commitment to transparency and best practice reporting.
“While we are proud of our progress, we remain committed to growing responsibly and further minimising our environmental impact”.
Looking ahead: healthcare with purpose
As healthcare systems worldwide seek more sustainable and equitable ways to deliver care, Diaverum is poised to lead – with Competence, Passion, and Inspiration. The company’s ambition is clear: to evolve from a treatment provider to an enabler of fulfilling lives. That means supporting patients beyond dialysis, strengthening health systems, and embedding sustainability into every decision the company makes.
While the implementation of the Corporate Sustainability Reporting Directive (CSRD) has been deferred by the EU’s Omnibus Directive, Diaverum will launch a new materiality assessment in 2025 and continue aligning its strategy with global best practices.
Diaverum’s 2024 ESG report is available through the company’s website.
-ENDS-
Marianna Sofocleous
Global Communications & Editorial Director
[email protected]
About Diaverum:
Diaverum is a Swedish-born, multinational healthcare organisation that provides life-enhancing renal care to patients with chronic kidney disease, empowering them to live fulfilling lives.
Our vision is to transform renal care, delivering and broadening access to the highest quality of kidney care for patients around the world. At the heart of what we do is our standardised care delivery model, continuously evolving digital & AI infrastructure and people caring for patients with competence, passion and inspiration.
As a global leader and the largest independent renal service provider in Europe, we have 13,500 healthcare professionals caring for around 42,000 patients across 450 clinics in 24 countries globally. We provide renal care personalised to patients’ needs and choices, offering a portfolio of treatments ranging from preventive care, haemodialysis, peritoneal dialysis and home care, to the coordination of patients’ comorbidities and holiday dialysis.
Founded in 1991 in Malmö, Sweden, Diaverum is part of the M42 group of companies, the global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet.
www.diaverum.com
link
